Healthcare Global Enterprises Ltd Q2 FY2026 Concall Summary

Key Takeaways

• KKR era begins with a strategic reset: KKR is now the majority shareholder and promoter, and management has unveiled a new cluster-based reporting framework, new performance metrics, and a sharper focus on sweating existing assets to unlock the 50%–60% of revenue potential still untapped at current pricing.
• The growth algorithm is shifting from footprint to depth: The next phase prioritizes deepening clinical programs, improving payor mix, and driving operating leverage from mature centres, with a target of 21%–22% EBITDA margin in the near term.
• Clinical outcomes are the economic moat: A 0.9% gross mortality rate, one-half to one-third of multispecialty peers, and survival rates that edge out leading global cancer institutes are being positioned as the foundation for pricing power and brand resilience.
• Milann is formally under strategic review: Management is evaluating several options, including a potential divestment, to sharpen the focus exclusively on cancer care.
• What to watch next quarter: The outcome of the ongoing pricing strategy exercise, any decision on the Milann vertical, and concrete steps on greenfield expansion in the 2–3 identified cities.

Strategic Reset Under KKR

• New ownership, new framework: KKR’s majority stake brings access to global healthcare expertise, long-term capital, and proven operating frameworks, and management has responded with a structural reset of how the business is reported and managed.
• Cluster-based organization: The old "established/emerging" classification is replaced by region-based clusters: South, West, East, and International (including Milann), designed to leverage regional synergies and improve accountability.
• New performance metrics: Occupancy and ARPOB are out; patient volumes and average realization per patient (ARPP) are in, alongside EBITDA margins and ROCE, aligning external reporting with how the business will be run.
• Senior leadership build-out: Five senior leaders hired in the past five months, including a first-ever Chief Marketing Officer, a Head of Clinical Strategy, a CIO, and heads for International and Domestic Sales, signalling a commercial and digital acceleration.

Manish Mattoo: "The thesis is simple: Specialist focus leads to better outcomes, stronger doctor performance, and strong economics."

The Revenue Potential Unlock

• Existing hospitals are only halfway there: Across all clusters, HCG operates at roughly 50%–60% of overall revenue potential at current pricing, assuming optimal occupancy and utilization, not 100%, making the upside practical and doable.
• The scale-profitability flywheel is visible: Hospitals generating ₹10 cr+ monthly revenue already deliver 25% EBITDA margin pre-corporate cost and ~27% ROCE, while the ₹5 cr–₹10 cr cohort (11 hospitals) delivers 20% margins and 12% ROCE, growing at 18% CAGR, creating a visible migration path.
• Growth deepens, it does not just expand: Mature centres grow by adding clinical teams, introducing complex programs like bone marrow transplants, upgrading technology from LINAC to robotic surgery, and shifting the specialty and payor mix, not just by filling beds.
• The timeline is four to five years at network level: Management acknowledged this is on the outer side and some centres like Ahmedabad can mature faster, but did not directly address why the network-level timeline is so long given most assets are already over five years old.

Manish Mattoo: "And you will notice across all the clusters, on average we are operating at about 50% to 60% of our overall revenue potential. So that is the key message I want to leave you with."

Clinical Moat & Competitive Positioning

• Mortality rate is the headline statistic: HCG’s 0.9% gross mortality rate is one-half to one-third of multispecialty peers, and despite a fourfold volume increase over 10 years, the rate decreased by 74%, a trend management calls very difficult to replicate.
• Survival rates beat global benchmarks: In a comparative study of five-year breast cancer survival rates, HCG’s outcomes were a couple of percentage points higher than a leading global cancer institute.
• The Tumour Board is a clinical engine, not just a forum: Over 40,000 cases discussed by roughly 400 oncologists and specialists, with insights systematically embedded into treatment protocols, directly contributing to low mortality, low relapse, and high survival rates.
• Scale advantage vs the next competitor: HCG has three times the installed LINAC base, two-and-a-half times the revenue, and two times the clinical density of the closest cancer-focused competitor.
• Multispecialty peers are not the threat: Management argues dedicated cancer centres are the global gold standard, and while cancer burden is rising fast enough for everyone to grow, HCG holds an edge on outcomes, quality of life, and survival rates.

Manish Mattoo: "Our gross mortality rate of just 0.9%, which is industry-leading... it is one half to one third of multi-specialty peer and it is something very difficult to replicate."

Margin & Return Profile

• Near-term margin target is 21%–22%: Management expects to reach this level in roughly three years, driven by operating leverage from revenue growth ahead of the industry, payor mix improvement, and procurement efficiencies.
• Mature centres show the long-term destination: Some mature centres already deliver 27%–28% EBITDA margin on a pre-corporate cost basis, and that is the long-term vision for the company overall, though no specific bridge or timeline was given for closing the gap to 25%–30%+ peer margins.
• ROCE is a new disclosed priority: Management expects a trend of at least 20%+ ROCE over the next five years, with improvement coming as the profile of higher-yielding centres improves.
• Balance sheet is already deleveraged: Net debt/EBITDA improved from 6.2x in FY2020 to 2.3x in FY2025, driven by cumulative EBITDA of ₹1,050 cr and 72% cash flow conversion, creating headroom for the next expansion cycle.
• Capex will stay disciplined: Maintenance capex is ₹90 cr–₹100 cr annually, with an additional ₹500 cr–₹600 cr over the next 2–3 years for brownfield and greenfield expansion, totalling roughly 30%–35% of EBITDA, funded through internal accruals and available borrowing headroom.

Manish Mattoo: "In near term, as I had given the margin guidance, that is the near term guidance of 21% to 22%. But as you see, some of our mature centres are delivering 27%-28% margin as well on a pre-corporate cost basis and that is the long term vision for the company overall."

Expansion & Capital Allocation

• Brownfield expansion is the near-term priority: Roughly 1,000 beds and 10 additional LINACs are planned through brownfield expansion in key markets like Ahmedabad, Cuttack, Baroda, and Vizag.
• Greenfield ambitions are measured: Management has identified 10–12 attractive cities and is confident of starting in at least 2–3 cities in the next 2–3 years, but no specific city or timeline was committed.
• Equity raise is under evaluation, not decided: When asked directly, management said they are evaluating the equity and debt ratio and will take an appropriate call at an appropriate time, a clear deflection without commitment.
• Milann divestment is on the table: Management confirmed they are evaluating several strategic options for the fertility vertical, including potential divestment, as the focus shifts entirely to cancer care.
• Asset-light adjacencies are in the mix: Investments in day-care centres and diagnostics are planned as complementary, capital-light growth drivers.

Payor Mix & Pricing Strategy

• Institutional business is being consciously shrunk: The 34% institutional payor mix, historically used to ramp up non-metro centres, will be reduced over the next three to four years by upgrading infrastructure, on-boarding clinical talent, and opening day-care centres in affluent micro-markets.
• International sales are a clear gap: At only 3% of overall sales, international revenue is well below potential given HCG’s clinical quality, and a dedicated sales leader has been hired to build relationships in Africa, the Middle East, and Southeast Asia.
• A pricing strategy exercise is underway: An annual pricing review is currently in progress and expected to conclude in the next couple of weeks, with management acknowledging there is definitely opportunity for price hikes in mature markets.
• Doctor incentive model favours fixed retainers: Most doctors are on a fixed retainer model, which management prefers for full-timers, though the Western cluster uses a fee-for-service model due to market constraints, and there is no intention to change the fixed model unless necessary.

Guidance & Commitments

Key Metrics